Global health regulatory bodies are updating evaluation protocols to expedite the clinical trial and approval processes for targeted RNA therapeutics.
Platform-Based Approvals
Regulators are shifting toward platform-based risk assessments. By evaluating delivery vectors separately from custom genetic payloads, agencies can accelerate review timelines for patient-specific therapies.
Manufacturing Scale Challenges
Despite regulatory progress, small-batch manufacturing of tailored RNA constructs remains expensive. Biotechnology firms are investing in automated, continuous-flow synthesis hardware to drive down unit production costs.